Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update
by Amy Steele · The Cerbat GemBiorestorative Therapies, Inc. (NASDAQ:BRTX – Get Free Report) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 647,105 shares, a drop of 27.4% from the March 31st total of 890,908 shares. Approximately 3.7% of the shares of the stock are short sold. Based on an average daily volume of 1,526,905 shares, the short-interest ratio is presently 0.4 days.
Institutional Trading of Biorestorative Therapies
Several hedge funds have recently modified their holdings of BRTX. Citadel Advisors LLC acquired a new position in shares of Biorestorative Therapies in the 3rd quarter worth approximately $152,000. DRW Securities LLC acquired a new stake in Biorestorative Therapies during the 4th quarter valued at $55,000. Finally, Virtu Financial LLC increased its holdings in Biorestorative Therapies by 102.4% during the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after purchasing an additional 12,319 shares in the last quarter. Institutional investors and hedge funds own 69.38% of the company’s stock.
Biorestorative Therapies Stock Performance
Shares of NASDAQ BRTX traded up $0.01 during midday trading on Friday, reaching $0.23. 834,722 shares of the company traded hands, compared to its average volume of 7,254,032. Biorestorative Therapies has a 12 month low of $0.19 and a 12 month high of $2.05. The stock’s 50-day simple moving average is $0.25 and its 200-day simple moving average is $0.85. The firm has a market cap of $5.94 million, a PE ratio of -0.15 and a beta of 0.37.
Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) last posted its earnings results on Thursday, March 26th. The company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.15 million. Biorestorative Therapies had a negative net margin of 3,956.11% and a negative return on equity of 430.91%. On average, equities research analysts expect that Biorestorative Therapies will post -0.66 EPS for the current year.
Biorestorative Therapies Company Profile
Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.
Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.